{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T04:07:04Z","timestamp":1770437224239,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":2668,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1093\/annonc\/mds128","type":"journal-article","created":{"date-parts":[[2012,6,23]],"date-time":"2012-06-23T01:12:26Z","timestamp":1340413946000},"page":"2082-2087","source":"Crossref","is-referenced-by-count":33,"title":["Zoledronic acid in patients with stage IIIA\/B NSCLC: results of a randomized, phase III study"],"prefix":"10.1016","volume":"23","author":[{"given":"G.V.","family":"Scagliotti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Kosmidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"de Marinis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.J.M.","family":"Schreurs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Albert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Engel-Riedel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Schallier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Barbera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.-P.","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Sallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.R.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Manegold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mds128_bb0010","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mds128_bb0015","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"10.1093\/annonc\/mds128_bb0020","doi-asserted-by":"crossref","first-page":"228","DOI":"10.6004\/jnccn.2008.0021","article-title":"Non-small cell lung cancer","volume":"6","author":"Ettinger","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1093\/annonc\/mds128_bb0025","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1097\/JTO.0b013e3181b68e5a","article-title":"Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel","volume":"4","author":"De Marinis","year":"2009","journal-title":"J Thorac Oncol"},{"issue":"Suppl. 1","key":"10.1093\/annonc\/mds128_bb0030","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1053\/j.seminoncol.2010.06.008","article-title":"Potential anticancer properties of bisphosphonates","volume":"37","author":"Neville-Webbe","year":"2010","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mds128_bb0035","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":"Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds128_bb0040","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/ijc.24470","article-title":"The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis","volume":"125","author":"Zarogoulidis","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mds128_bb0045","series-title":"Zoledronic acid delays disease progression and improves survival in patients with bone metastases from solid tumors and elevated levels of bone resorption","author":"Costa","year":"2009"},{"key":"10.1093\/annonc\/mds128_bb0050","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1385\/MO:22:2:195","article-title":"Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline","volume":"22","author":"Mystakidou","year":"2005","journal-title":"Med Oncol"},{"key":"10.1093\/annonc\/mds128_bb0055","series-title":"Zometa\u00ae (zoledronic acid) injection [package insert]","year":"2011"},{"key":"10.1093\/annonc\/mds128_bb0060","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mds128_bb0065","series-title":"Common Terminology Criteria for Adverse Events v3.0 (CTCAE)","author":"Cancer Therapy Evaluation Program","year":"2006"},{"key":"10.1093\/annonc\/mds128_bb0070","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1093\/annonc\/mds128_bb0075","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0889-8588(03)00138-2","article-title":"Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data","volume":"18","author":"Reboul","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1093\/annonc\/mds128_bb0080","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/JTO.0b013e3181651c0e","article-title":"Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity","volume":"3","author":"Hirsh","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mds128_bb0085","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1158\/1078-0432.CCR-07-4749","article-title":"Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse","volume":"14","author":"Bidard","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mds128_bb0090","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMoa050434","article-title":"A pooled analysis of bone marrow micrometastasis in breast cancer","volume":"353","author":"Braun","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds128_bb0095","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1470-2045(10)70054-1","article-title":"Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial","volume":"11","author":"Aft","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mds128_bb0100","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.lungcan.2007.03.013","article-title":"Skeletal metastases in non-small cell lung cancer: a retrospective study","volume":"57","author":"Tsuya","year":"2007","journal-title":"Lung Cancer"},{"key":"10.1093\/annonc\/mds128_bb0105","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.lungcan.2009.04.020","article-title":"Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer","volume":"67","author":"Pandya","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1093\/annonc\/mds128_bb0110","first-page":"2893","article-title":"Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients","volume":"9","author":"Santini","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mds128_bb0115","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1080\/14653240802419328","article-title":"Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy","volume":"10","author":"Kondo","year":"2008","journal-title":"Cytotherapy"},{"key":"10.1093\/annonc\/mds128_bb0120","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/ijc.20987","article-title":"Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy","volume":"116","author":"Sato","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mds128_bb0125","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1007\/s00259-004-1492-2","article-title":"Omission of bone scanning according to staging guidelines leads to futile therapy in non-small cell lung cancer","volume":"31","author":"Schirrmeister","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341938127X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341938127X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/8\/2082\/13788732\/mds128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T09:39:45Z","timestamp":1624441185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341938127X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S092375341938127X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mds128","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}